WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

BOCOM International: Optimistic about the leading biologic drug CDMO with advanced ADC R&D platform WuXi Biologics (02269 HK) https://www.finet.hk/newscenter/news_content/60d2857dbde0b3600d149c64 ...Globally, 10 ADC products have been approved by the U.S. FDA. The launch of the first domestic ADC drug is a milestone event for China's biopharmaceuticals. We are optimistic about the leading biologic drug CDMO with advanced ADC R&D platform WuXi Biologics (02269 HK), Give a buy rating and a target price of HK$143.1.

WuXi Biologics (02269) hat kürzlich insgesamt rund 16,283 Millionen zusätzliche Aktien ausgegeben https://m.jrj.com.cn/madapter/hk/2021/06/23073932980506.shtml WuXi Biologics (02269) gab bekannt, dass vom 1. bis 22. Juni 2021 insgesamt rund 16,283 Millionen zusätzliche Aktien aufgrund der Ausübung von Aktienoptionen und der Gewährung gesperrter Aktien ausgegeben werden.

WuXi Biologics (02269 HK) hat aufgrund der Ausübung von Aktienoptionen am 22. Juni insgesamt 3,247 Millionen Aktien ausgegeben https://m.jrj.com.cn/madapter/hk/2021/06/23073832980485.shtml

Guten Morgen, ja, der Ausblick ist doch nicht verkehrt 😎

Guten Morgen, das sieht bei WuXi alles sehr gut aus😊👍🏼!!!

Blue chip stocks 2021 - WuXi Biologics has high profitability visibility, stock price continues to hit a new high and has not reached its peak, new target price of 151.8 yuan to attack strategy https://www.businesstimes.com.hk/articles/133790/%E8%97%A5%E6%98%8E%E7%94%9F%E7%89%A9-%E9%86%AB%E8%97%A5%E8%82%A1-%E6%B8%AF%E8%82%A1-%E7%BE%8E%E8%82%A1-%E6%81%92%E6%8C%87-%E9%84%A7%E8%81%B2%E8%88%88-%E6%9C%89%E8%81%B2%E6%9C%89%E8%AD%98

Zhongtai International: New orders from WuXi Biologics (02269 HK) exceed expectations and target price rises to HK$150.3 https://www.finet.hk/newscenter/news_content/60d14b7bbde0b3600d149bbe Daiwa: Reiterate WuXi Biologics (02269) "Buy" rating target price rose 19.3% to HK$167 https://hk.investing.com/news/stock-market-news/article-172678

Credit Suisse: WuXi Biologics (02269) "Outperform"-Rating beibehalten und Kursziel um 21.5% auf HK$158 anheben https://hk.investing.com/news/stock-market-news/article-172458 Morgan Stanley: Das Kursziel für WuXi Biologics (02269) "Übergewichten" wird um 8,6% auf HK$152 angehoben https://finance.sina.cn/hkstock/ggpj/2021-06-21/detail-ikqcfnca2298600.d.html?from=wap Goldman Sachs: WuXi Biologics (02269) „Kaufen“-Rating-Kursziel erneut um 20% auf 157,9 Hongkong-Dollar angehoben https://m.jrj.com.cn/madapter/hk/2021/06/21132932968995.shtml

🍀👍

😊👍🏼

HSI Once Slumps 435 Pts before Cutting Plunge; HSBC Once Dives to Around $45; Yet WUXI BIO Up Almost 5% http://www.aastocks.com/en/stocks/news/aafn-con/RUM.210621_101546/recommend-news The HSI, once deepening the plunge to 435 pts to bottom at 28,365 before holding steady, ... On  the contrary, WUXI BIO (02269 HK) last traded at $138.6, up 4.9%, with target prices being raised to $152-158 by Morgan Stanley/ Goldman Sachs/ Credit Suisse after the company's management had raised the full-year profit forecast.

Könnten gerne das Kursziel 'anpassen' 😉

Macquarie: Reiterate WuXi Biologics (2269 HK) "Outperform" rating target price of HK$122 https://m.jrj.com.cn/madapter/hk/2021/06/18160332954824.shtml According to a research report published by Macquarie, the CEO of WuXi Biologics (2269 HK) announced that it will raise its guidance for full-year sales and profit growth from 50% to 65%, which is higher than the bank’s expected 57%. It is expected to be in the industry. With rapid growth, the company will continue to perform strongly in the next few years, with a compound annual growth rate of 38% to 50%. The bank pointed out that there are currently 9 vaccine projects under development or production, providing good support for growth. The management’s goal is to increase the number of projects under development to 80 in the future. Macquarie expects that 4 to 5 of the 32 phase III clinical phase products in hand will be core projects, and the peak sales of each can reach US$4 billion to US$5 billion. In addition, peak sales of 4 to 5 Phase III projects are also expected to reach more than US$1 billion, providing the company with a stable source of income. Macquarie pointed out that WuXi Biologics management aims to become the industry's first in the next three years, and reiterated its "Outperform" rating with a target price of HK$122.

Und noch einer 🙃:

Gerne! Gerade über die letzten News hatte ich mich gefreut 🍀😀

Vielen lieben Dank für die Infos, Summer.76🙏🏼!!!